Cover Image
市場調查報告書

整合素αV :開發中產品分析

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 367835
出版日期 內容資訊 英文 75 Pages
訂單完成後即時交付
價格
Back to Top
整合素αV :開發中產品分析 Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2016
出版日期: 2016年07月27日 內容資訊: 英文 75 Pages
簡介

本報告提供以整合素αV 為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。。

簡介

  • 調查範圍

整合素αV 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥開發企業

  • Biogen, Inc.
  • BioMAS Ltd.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • SciFluor Life Sciences, LLC
  • Tissue Therapies Limited
  • TWi Pharmaceuticals, Inc.
  • Vascular Pharmaceuticals, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0408TDB

Summary

Global Markets Direct's, 'Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2016', provides in depth analysis on Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted pipeline therapeutics.

The report provides comprehensive information on the Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)
  • The report reviews Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Overview
    • Therapeutics Development
  • Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Products under Development by Stage of Development
  • Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Products under Development by Therapy Area
  • Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Products under Development by Indication
  • Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Products under Development by Companies
  • Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Products under Development by Universities/Institutes
  • Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Companies Involved in Therapeutics Development
    • Biogen, Inc.
    • BioMAS Ltd.
    • MedImmune, LLC
    • Merck & Co., Inc.
    • SciFluor Life Sciences, LLC
    • Tissue Therapies Limited
    • TWi Pharmaceuticals, Inc.
    • Vascular Pharmaceuticals, Inc.
  • Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Drug Profiles
    • 264-RAD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AC-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibodies to Inhibit AlphaVBeta6 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AS-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BG-00011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-16Y - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cilengitide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-0429 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OCU-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Melanoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Proagio - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RSF-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SF-0166 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize AlphaVBetaI for Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tetraiodothyroacetic acid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VF-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VF-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VF-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VF-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPI-2690B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Dormant Projects
  • Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Discontinued Products
  • Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Featured News & Press Releases
    • May 31, 2016: New Class of Protein Could Treat Cancer and Other Diseases, Georgia State Researchers Find
    • May 25, 2016: Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology
    • Mar 09, 2016: SciFluor Life Sciences Awarded Second U.S. Patent for Integrin avß3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease
    • Feb 11, 2016: Ocugen Announces Patent Allowance For Ocu-200
    • Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update
    • Feb 25, 2013: Merck Serono Announces Phase III Trial Of Cilengitide Did Not Meet Primary Endpoint In Patients With Newly Diagnosed Glioblastoma
    • Jun 09, 2011: Merck Serono Completes Patient Enrollment For Cilengitide's Pivotal Phase III Trial CENTRIC
    • Aug 31, 2010: Stromedix Receives FDA Orphan Drug Designation For STX-100 For Treatment Of Idiopathic Pulmonary Fibrosis
    • Jun 05, 2010: EMD Serono Announces Long-Term Follow-up Data From Cilengitide Study In Glioblastoma Patients
    • May 31, 2009: Study Shows Cilengitide Increased Overall Survival In Patients With Glioblastoma
    • Mar 16, 2009: Merck Serono Expands Cilengitide Development Program
    • Jan 22, 2009: Stromedix Secures Broad Patent Coverage For Lead Program, Including Compositions Related To Its Lead Product, STX-100
    • Aug 12, 2008: Stromedix Receives Orphan Drug Designation For STX-100 In Chronic Allograft Nephropathy
    • Jan 01, 2004:
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Biogen, Inc., H2 2016
  • Pipeline by BioMAS Ltd., H2 2016
  • Pipeline by MedImmune, LLC, H2 2016
  • Pipeline by Merck & Co., Inc., H2 2016
  • Pipeline by SciFluor Life Sciences, LLC, H2 2016
  • Pipeline by Tissue Therapies Limited, H2 2016
  • Pipeline by TWi Pharmaceuticals, Inc., H2 2016
  • Pipeline by Vascular Pharmaceuticals, Inc., H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Dormant Projects (Contd..2), H2 2016
  • Dormant Projects (Contd..3), H2 2016
  • Dormant Projects (Contd..4), H2 2016
  • Discontinued Products, H2 2016
  • Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top